Skip to content
Advanced Analysis
Free Trading Signals
Real-Time Alerts
Data & Analytics

Neimeth International Pharmaceutical Plc (NGX: NEIMETH) | Share Price

Nigel Firth
Nigel Frith trader
Updated 20 May 2024
OPEN DEMO TRADING ACCOUNT YOUR CAPITAL IS AT RISK. 76% OF RETAIL CFD ACCOUNTS LOSE MONEY
Neimeth International Pharmaceutical Plc

Neimeth International Pharmaceutical Plc is a pharmaceutical company listed on the Nigerian Stock Exchange (NGX).

Overview of Neimeth International Pharmaceutical Plc

Neimeth International Pharmaceutical Plc is involved in the manufacturing and marketing of pharmaceuticals and animal health products from one of the most modern pharmaceutical manufacturing plants in Oregun, Lagos, West Africa.

Today, Neimeth International Pharmaceutical Plc’s portfolio of products and services are diversified in more sectors of the Health Care value chain and include the following: manufacturing, distribution and marketing of Pfizer brands of pharmaceutical and veterinary products in tablets, capsules, ointment, powder, injectables and oral liquid forms.

The history of Neimeth International Pharmaceutical Plc goes back to 1957 when the company was founded, and it had been listed on 21 September 1979.

Neimeth International Pharmaceutical Plc has its head offices at Plot 16, Akanni Doherty Layout, Oregun Industrial Estate, Oregun, Lagos, Nigeria.

The company renders its services in Ghana, Sierra Leone, Liberia and the Gambia.

The current CEO/managing director of Neimeth International Pharmaceutical Plc is Matthew Obi Azoji.

Neimeth Pharma

Neimeth International Pharmaceutical Plc's equity stocks are for sale online on the Nigerian Stock Exchange (NGX) under the stock symbol NEIMETH.

Neimeth International Pharmaceutical Plc forms part of the Biotechnology and Drugs Industry and the Health Care Sector of the Nigerian Stock Exchange (NGX).

Neimeth International Pharmaceutical Plc Stock Performance

The current price for Neimeth International Pharmaceutical Plc stocks on the Nigerian Stock Exchange (NGX) is 1.63 Nigerian Naira (NGN).

An analysis of financial data of Neimeth International Pharmaceutical Plc showed that the company has a total market capitalisation of 3.1 Billion NGN, with a Price/Earning ratio of 81.50 and earnings per share of 0.02 NGN.

With an increase of earnings per share and reliable profits over a period, investors who want to buy or sell Neimeth International Pharmaceutical Plc stocks can look forward to more profitable dividends and earnings in times to come.

According to an analysis on the live chart of Neimeth International Pharmaceutical Plc, analysts forecast further improved performance for the Health Care sector with market share growing as trading volumes increase.

Highlights of Neimeth International Pharmaceutical Plc in 2021

Neimeth International Pharmaceutical Plc started the current financial year (2021) with a share price of 2.23 Nigerian Naira (NGN) on the Nigerian Stock Exchange (NGX), and it has lost 26.9 % in value on its price valuation, ranking 143rd on the NGX with its year-to-date performance.

NEIMETH has lost 18% of its value from November 12th to date.

Neimeth International Pharmaceutical Plc is currently the 71st most-traded stock on the NGX and it has experienced a total trading volume of more than 19.7 million shares, which were finalised in 857 deals and were valued at a total of 35.2 million Nigerian Naira (NGN) over the recent three month period from September to December 2021, with an average of 312,171 shares in each trading session.

During the same period a volume high of 2.04 million was achieved on November 10 and a low of 10,079 on September 24.

Neimeth Pharma - How To Trade

How to buy Neimeth International Pharmaceutical Plc stocks – Step by Step

The stock market is one of the most attractive financial markets that sees millions of retail investors and traders participating daily. To buy, sell or trade Neimeth International Pharmaceutical Plc stocks on the Nigerian Stock Exchange (NGX), traders and investors can follow a few simple steps:

  1. Find the share that you want to buy, in this case, “NEIMETH”.
  2. Select a forex broker that offers access to the Nigerian Stock Exchange (NGX).
  3. Review the broker's trading conditions, fees, deposit and withdrawal methods, trading platform, customer support, regulation, and other components to ensure that they are aligned with your trading plan.
  4. Open a live trading account with the broker by completing the online application form and providing the necessary documentation to verify the trading account.
  5. Once your account has been activated, you are ready to make your first share purchase through the broker.
  6. From here you can start to build and diversify your portfolio by buying more shares.

FAQs

The Nigerian Stock Exchange (NGX) (officially the Nigerian Exchange Group) is a leading integrated market organisation in Africa servicing the continent’s largest economy, that of Nigeria. The Exchange provides capital access to companies that seek to take advantage of the financial markets to fund their business expansion. The NGX also provides its collection of domestic, regional, and international investors with an array of regulated securities to achieve their investment objectives.

The NGX publishes the benchmark, value-weighted All-Share Index (ASI), formulated in January 1984 with a base value of 100 and which tracks the general market movement of all listed equities on the Exchange.

The NGX30 and NGX50 are additional indices that track the top 30 and 50 companies in terms of market capitalization and liquidity respectively. Only fully paid-up common shares weighted by adjusted market capitalization are admitted to these indices.

In March 2021, the Nigerian Stock Exchange was transformed into a shareholder-owned, profit making entity, the Nigerian Exchange Group Plc, when it was demutualised from a member-owned not-for-profit entity.

People Who Read This Also Read:

Nigel Firth
Nigel Frith trader
Nigel has been in the regulated financial services industry for nearly a decade, has previously owned a financial brokerage and has written many times for sites relating to personal finance and trading.